entity

NAD+ depletion

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about NAD+ depletion: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

7Connections
0Hypotheses
1Analyses
6Outgoing
1Incoming
0Experiments
2Debates

No AI portrait yet

Outgoing (6)

TargetRelationTypeStr
Agingassociated_withdisease0.85
Metabolic Disordersassociated_withdisease0.85
Agingassociated_withdisease0.85
Neurodegenerationassociated_withdisease0.85
Neurodegenerationassociated_withdisease0.80

Incoming (1)

SourceRelationTypeStr
NEURODEGENERATIVE DISORDERSassociated_withgene0.60

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
No targeting hypotheses

Mentioning Analyses (1)

Scientific analyses that reference this entity

Clinical Trial Landscaping for Alzheimer's Disease Therapeutics

neurodegeneration | 2026-04-16 | 0 hypotheses

Experiments (0)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
No papers found

Debates (2)

Multi-agent debates referencing this entity

What is the current clinical trial landscape for AD therapeutics, and which mech

closed · Rounds: 4 · Score: 0.30 · 2026-04-21

Is the amyloid concentration in AD clinical trials rational given lecanemab's ap

closed · Rounds: 4 · Score: 0.70 · 2026-04-16